Frequently Asked Questions
Is cannabis legal in Australia?
In 2016, The Therapeutic Goods Administration (TGA) reclassified medicinal cannabis products containing tetrahydrocannabinols (THC) from Schedule 9 (prohibited) to schedule 8 (controlled) of the Poisons Standard, making the prescription of medicinal cannabis containing THC legal in Australia. Cannabidiol (CBD) products (which have less than 2% of any other active component) remain at Schedule 4, and have much less restriction than Schedule 8 products.
A patient must receive an approval from the TGA and/or State Health Authority, and a prescription from a medical practitioner to legally possess and consume medicinal cannabis.
Recreational use remains illegal across all federal, state, and territories in Australia.
Who can grow and sell medicinal cannabis?
Federal legislation in Australia allows organisations to apply for a licence to cultivate medicinal cannabis with the Commonwealth Government’s Office of Drug Control. Currently, only one Australian company has medicinal cannabis for sale in the domestic market. A list of companies that are currently exporting/importing medicinal cannabis products to Australia is available on the Office of Drug Control website, but their availability is not guaranteed to patients.
Medicinal cannabis products are dispensed through Pharmacies. Usually, the prescribing physician will choose a pharmacy that is most convenient for the patient.
Tetra Health has access to a consistent and diverse supply of GMP certified, TGO93 Approved medicinal cannabis medicines for its patients.
How long does it take to get A TGA approval?
As of 30 July 2018 an online system was introduced to enable the lodgement of Special Access Scheme (SAS) applications and notifications. This TGA online system includes functionality that will now allow prescribers in certain States and Territories to submit an application and proper supporting documentation to both the Commonwealth and the relevant State/Territory Health Department simultaneously. Prior to the introduction of this system, prescribers of unapproved medicinal cannabis products were required to complete and separately submit paper forms to the TGA and relevant State Health Department.
Further information on the SAS online system and details on the submission of medicinal cannabis applications can be found at: Special Access Scheme online system
The current processing time for approval by the TGA is approximately 48 hours, and State Health Authorities can take up to one week or longer, pending Requests for Information on incomplete or incorrect applications.
How does cannabis work?
The Endocannabinoid System is a complex regulatory system made up of receptors, molecules called endocannabinoids, and enzymes that either synthesize or metabolize those endocannabinoids. The main function of the endocannabinoid system is to regulate the human body by maintaining homeostasis.
The cannabis plant produces more than 500 different chemical compounds, including over 120 phytocannabinoids (like THC and CBD), 30 (known) terpenes (like linalool and myrcene), flavonoids and hundreds of other compounds; but fewer than 50 of these compounds are produced in significant amounts.
CB1 receptors are found primarily in the nervous system while CB2 receptors are found predominately the immune system, however both receptors can be found in various organs throughout the body. The mapping of these receptors fits well with the diverse range of symptoms and conditions that are found to respond positively to medicinal cannabis, and the synergistic effect (known as the Entourage Effect) of these different compounds working together in each unique strain/medicine is what causes such diverse effects.
What conditions or symptoms could cannabis treat?
In order for the government to approve an authorisation for medicinal cannabis, there must be enough evidence supporting the benefits of treatment.
Currently, there are no restrictions imposed by the TGA on the indications/conditions for which a medical practitioner may apply for medical cannabis for their patient. The body of clinical evidence continues to grow daily, meaning a variety of other conditions may be recognized to have positive associated outcomes with cannabinoid medications.
To date, the TGA has approved SAS applications including, but not limited to, the following indications:
- chronic pain
- chemotherapy-induced nausea and vomiting
- refractory paediatric epilepsy
- palliative care indications
- cancer pain
- neuropathic pain
- spasticity from neurological conditions
- anorexia and wasting associated with chronic illness
- and many more..
How are medicinal cannabis medicines taken?
Are there side effects from taking medicinal cannabis?
- Tachycardia (rapid heartbeat) is common among novice users;
- Dry mouth (cottonmouth);
- Dizziness or light-headedness;
- Red, irritated eyes;
- Coughing caused by inhaled cannabis (combustion), or vaporized cannabis.
Is there a difference between recreational cannabis and medicinal cannabis?
How can I get approval for medicinal cannabis?
Is medicinal cannabis covered by the PBS?
No, medicinal cannabis is not currently covered by the Pharmaceutical Benefits Scheme (PBS). To be included on the PBS, the medicine must be registered and approved by the TGA. To be approved, the medicine must be shown safe and effective through clinical trials. The current challenge is that until recently, cannabis has been a prohibited product, and has limitations of being patented as a new drug. Some medicinal cannabis trials are currently underway for various products, but it is unknown how long it will take for them to receive TGA approval.
Tetra has assisted numerous patients retrieve medical cannabis reimbursements through the Department of Veteran Affairs, Work Cover, ComCare and Private Health Funds. Please enquire about this during your Nurse Consultation and our team would be happy to assist.
How much do cannabis medicines cost?
Currently, medical cannabis products are quite costly in Australia. The high cost of product is largely because 90% of the medicines available in Australia are being imported from Canada or Europe. In the next 6 months, Tetra will offer lower cost products that are produced locally in Australia as they become available.
The current cost of cannabis medication per patient varies greatly. Cost is dependant on the type of medicine that is prescribed (i.e. oil, flower, capsule), dosage and the indication being treated. A patient could expect to pay, at least $200 per month.
In addition to the above variables, numerous studies have shown the enormous range of effects occurring when cannabis medicines are administered to different patients. This variance depends on several factors: cannabis use pattern, additional drugs being taken, genetic variations and how the cannabis is administered, etc. When administered orally, for example, the amount of THC that will make it into the bloodstream will vary between 4 and 20 percent.
Will my health insurance cover any costs?
At this time, Health Insurance does not cover the cost of cannabis medications, as they are not listed on the PBS. In person consultations and follow-up appointments with a general practitioner or specialist for the purpose of medicinal cannabis assessment are covered under Medicare. Tetra has assisted certain patients retrieve some costs for their appointments / medication through their private health fund. Please discuss this with your nurse during your consultation.